Effects of peripheral glutamate receptors on tumor cell growth - how neurotransmitters can affect the body

Progress in Cell Growth Process Research

Volumn , Issue , 2008, Pages 209-219

  Haas, Helga Susanne ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649488223     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (62)

1. Abdul, M; Hoosein, N. N-methyl-D-aspartate receptor in human prostate cancer. J. Membr. Biol., 2005, 205, 125-128.
2. Arcella, A; Carpinelli, G; Battaglia, G; D'Onofrio, M; Santoro, F; Ngomba, RT; Bruno, V; Casolini, P; Giangaspero, F; Nicoletti, F. Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol., 2005, 7, 236-245.
3. Behar, TN; Scott, CA; Greene, CL; Wen, X; Smith, SV; Maric, D; Liu, QY; Colton, CA; Barker, JL. Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. J. Neurosci., 1999, 19, 4449-4461.
4. Bennett, MR; Balcar, VJ. Forty years of amino acid transmission in the brain. Neurochem. Int., 1999, 35, 269-280.
5. Besedovsky, HO; del Rey, A. Physiology of psychoneuroimmunology: a personal view. Brain Behav. Immun., 2007, 21, 34-44.
6. Blalock, JE; Smith, EM. Conceptual development of the immune system as a sixth sense. Brain Behav. Immun., 2007, 21, 23-33.
7. Carling, T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr. Opin. Oncol., 2005, 17, 7-12.
8. Cavalheiro, EA; Olney, JW. Glutamate antagonists: deadly liaisons with cancer. Proc. Natl. Acad. Sci. USA, 2001, 98, 5947-5948.
9. Chang, HJ; Yoo, BC; Lim, S-B; Jeong, S-Y; Kim, WH; Park, J-G. Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin. Cancer Res., 2005, 11, 3288-3295.
10. Choi SW, Park SY, Hong SP, Pai H, Choi JY, Kim SG. The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinoma. J. Oral. Pathol. Med., 2004, 33, 533-537.
11. de Rivero Vaccari, JC; Casey, GP; Aleem, S; Park, WM; Corriveau, RA. NMDA receptors promote survival in somatosensory relay nuclei by inhibiting Bax-dependent developmental cell death. Proc. Natl. Acad. Sci. U S A, 2006, 103, 16971-16976.
12. D'Onofrio, M; Arcella, A; Bruno, V; Ngomba, RT; Battaglia, G; Lombari, V; Ragona, G; Calogero, A; Nicoletti, F. Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J. Neurochem., 2003, 84, 1288-1295.
13. Gill, S; Pulido, O. Glutamate receptors in peripheral tissue. 1. Edition. New York: Kluwer Academic/Plenum Publishers; 2005.
14. Haas, HS; Schauenstein, K. Neuroimmunomodulation via limbic structures--the neuroanatomy of psychoimmunology. Prog. Neurobiol., 1997, 5, 195-222.
15. Haas, HS; Schauenstein, K. Immunity, hormones, and the brain. Allergy, 2001, 5, 470-477.
16. Haas, HS; Pfragner, R; Siegl, V; Ingolic, E; Heintz, E; Schauenstein, K. Glutamate receptormediated effects on growth and morphology of human histiocytic lymphoma cells. Int. J. Oncol., 2005, 27, 867-74.
17. Haas, HS; Pfragner, R; Siegl, V; Ingolic, E; Heintz, E; Schraml, E; Schauenstein, K. The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma. Int. J. Oncol., 2007, 17, 1399-1404.
18. Heijnen, CJ. Receptor regulation in neuroendocrine-immune communication: current knowledge and future perspectives. Brain Behav. Immun., 2007, 21, 1-8.
19. Hetman, M; Kharebava G. Survival signaling pathways activated by NMDA receptors. Curr. Top Med. Chem., 2006, 6, 787-799.
20. Hinoi, E; Takarada, T; Ueshima, T; Tsuchihashi, Y; Yoneda, Y. Glutamate signaling in peripheral tissues. Eur. J. Biochem., 2004, 271, 1-13.
21. Hoang, BX; Levine, SA; Pham, P; Shaw, DG. Hypothesis of the cause and development of neoplasms. Eur. J. Cancer Prev., 2007, 16, 55-61.
22. Iacovelli, L; Arcella, A; Battaglia, G; Pazzaglia, S; Aronica, E; Spinsanti, P; Caruso, A; De Smaele, E; Saran, A; Gulino, A; D'Onofrio, M; Giangaspero, F; Nicoletti, F. Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J. Neurosci., 2006, 26, 8388-8397.
23. Ikonomidou, C; Bosch, F; Miksa, M; Bittigau, P; Vockler, J; Dikranian, K; Tenkova, TI; Stefovska, V; Turski, L; Olney, JW. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science, 1999, 283, 70-74.
24. Ishiuchi, S; Tsuzuki, K; Yoshida, Y; Yamada, N; Hagimura, N; Okado, H; Miwa, A; Kurihara, H; Nakazato, Y; Tamura, M; Sasaki, T; Ozawa, S. Blockage of Ca2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat. Med., 2002, 8, 971-978.
25. Ishiuchi, S; Yoshida, Y; Sugawara, K; Aihara, M; Ohtani, T; Watanabe, T; Saito, N; Tsuzuki, K; Okado, H; Miwa, A; Nakazato, Y; Ozawa, S. Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J. Neurosci., 2007, 27, 7987-8001.
26. Kalariti, N; Lembessis, P; Koutsilieris, M. Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res., 2004, 24, 3923-2929.
27. Kalariti, N; Pissimissis, N; Koutsilieris, M. The glutamatergic system outside the CNS and in cancer biology. Expert Opin Investig Drugs, 2005, 14, 1487-1496.
28. Kew, JNC. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol. Ther., 2004, 104, 233-244.
29. Kew, JNC; Kemp, JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology, 2005, 179, 4-29.
30. Kim, MS; Yamashita, K; Baek, JH; Park, HL; Carvalho, AL; Osada, M; Hoque, MO; Upadhyay, S; Mori, M; Moon, C; Sidransky, D. N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res., 2006, 66, 3409-3418.
31. Leung, JC; Travis, BR; Verlander, JW; Sandhu, SK; Yang, SG; Zea, AH; Weiner, ID; Silverstein, DM. Expression and developmental regulation of the NMDA receptor subunits in the kidney and cardiovascular system. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2002, 283, R964-R971.
32. Li, S; Huang, S; Peng, S-B. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int. J. Oncol., 2005, 27, 1329-1339.
33. Liu, JW; Kim, MS; Nagpal, J; Yamashita, K; Poeta, L; Chang, X; Lee, J; Park, HL; Jeronimo, C; Westra, WH; Mori, M; Moon, C; Trink, B; Sidransky D. Quantitative hypermethylation of NMDAR2B in human gastric cancer. Int. J. Cancer, 2007, in press.
34. Lombardi, G; Dianzani, C; Miglio, G; Canonico, PL; Fantozzi, R. Characterization of ionotropic glutamate receptors in human lymphocytes. Br. J. Pharmacol., 2001, 133, 936-944.
35. Lucas, DR; Newhouse, JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch. Ophthalmol., 1957, 58, 193-201
36. Luján, R; Shigemoto, R; López-Bendito, G. Glutamate and GABA receptor signalling in the developing brain. Neuroscience, 2005, 130, 567-580.
37. Marín, YE; Namkoong, J; Cohen-Solal, K; Shin, S-S; Martino, JJ; Oka, M; Chen, S. Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal, 2006, 18, 1279-1286.
38. Monson, JP. The epidemiology of endocrine tumors. Endocr Rel Cancer, 2000, 7, 29-36.
39. Namkoong, J; Shin, SS; Lee, HJ; Marin, YE; Wall, BA; Goydos, JS; Chen, S. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res., 2007, 67, 2298-2305.
40. Nedergaard, M; Takano, T; Hansen AJ. Beyond the role of glutamate as a neurotransmitter. Nat. Rev. Neurosci., 2002, 3, 748-755.
41. Nicoletti, F; Bruno, V; Catania, MV; Battaglia, G; Copani, A; Barbagallo, G; Cena, V; Sanchez-Prieto, J; Spano, PF; Pizzi, M. Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology, 1999, 38, 1477-1484.
42. Nicoletti, F; Arcella, A; Iacovelli, L; Battaglia, G; Giangaspero, F; Melchiorri, D. Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol. Sci., 2007, 28, 206-213.
43. Ozawa, S; Kamiya, H; Tsuzuki, K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol, 1998, 54, 581-618.
44. Pacheco, R; Ciruela, F; Casadó, V; Mallol, J; Gallart, T; Lluis, C; Franco, R. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J. Biol. Chem., 2004, 279, 33352-33358.
45. Park, SY; Lee, SA; Han, IH; Yoo, BC; Lee, SH; Park, JY, Cha, IH; Kim, J; Choi, SW. Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol. Rep., 2007, 17, 81-87.
46. Pin, JP; Acher, F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr. Drug. Targets CNS Neurol. Disord., 2002, 1, 297-317.
47. Pollock, PM; Cohen-Solal, K; Sood, R; Namkoong, J; Martino, JJ; Koganti, A; Zhu, H; Robbins, C; Makalowska, I; Shin, SS; Marin, Y; Roberts, KG; Yudt, LM; Chen, A; Cheng, J; Incao, A; Pinkett, HW; Graham, CL; Dunn, K; Crespo-Carbone, SM; Mackason, KR; Ryan, KB; Sinsimer, D; Goydos, J; Reuhl, KR; Eckhaus, M; Meltzer, PS; Pavan, WJ; Trent, JM; Chen, S. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat. Genet., 2003, 34, 108-112.
48. Ritzén, A; Mathiesen, JM; Thomsen, C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin. Pharmacol. Toxicol., 2005, 97, 202-213.
49. Rothstein, JD; Brem, H. Excitotoxic destruction facilitates brain tumor growth. Nat. Med., 2001, 7, 994-995.
50. Rzeski, W; Turski, L; Ikonomidou, C. Glutamate antagonists limit tumor growth. Proc. Natl. Acad. Sci. USA, 2001, 98, 6372-6377.
51. Skerry, TM; Genever, PG. Glutamate signalling in non-neuronal tissues. Trends Pharmacol. Sci., 2001, 22, 174-181.
52. Sontheimer, H. Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci., 2003, 26, 543-549.
53. Steinman, L. Elaborate interactions between the immune and nervous systems. Nat. Immunol., 2004, 5, 575-581.
54. Stepulak, A; Sifringer, M; Rzeski, W; Endesfelder, S; Gratopp, A; Pohl, EE; Bittigau, P; Felderhoff-Mueser, U; Kaindl, AM; Buhrer, C; Hansen, HH; Stryjecka-Zimmer, M; Turski, L; Ikonomidou, C. NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci U S A, 2005, 102, 15605-15610.
55. Storto, M; de Grazia, U; Battaglia, G; Felli, MP; Maroder, M; Gulino, A; Ragona, G; Nicoletti, F; Screpanti, I; Frati, L; Calogero; A. Expression of metabotropic glutamate receptors in murine thymocytes and thymic stromal cells. J. Neuroimmunol., 2000, 109, 112-120.
56. Takano, T; Lin, JH-C; Arcuino, G; Gao, Q; Yang, J; Nedergaard, M. Glutamate release promotes growth of malignant tumors. Nat. Med., 2001, 7, 1010-1015.
57. Thakker, RV. Multiple endocrine neoplasia. Horm. Res., 2001, 56, 67-72.
58. Tsibris, JC; Maas, S; Segars, JH; Nicosia, SV; Enkemann, SA; O'Brien, WF; Spellacy, WN. New potential regulators of uterine leiomyomata from DNA arrays: the ionotropic glutamate receptor GluR2. Biochem Biophys Res Commun., 2003, 312, 249-254.
59. Vincent, AM; Maiese K. The metabotropic glutamate system promotes neuronal survival through distinct pathways of programmed cell death. Exp Neurol, 2000, 166, 65-82.
60. Yoo, BC; Jeon, E; Hong, SH; Shin, YK; Chang, HJ; Park JG. Metabotropic glutamate receptor 4-mediated 5-Fluorouracil resistance in a human colon cancer cell line. Clin. Cancer Res., 2004, 10, 4176-4184.
61. Yoshida, Y; Tsuzuki, K; Ishiuchi, S; Ozawa, S. Serum-dependence of AMPA receptormediated proliferation in glioma cells. Pathol. Int., 2006, 56, 262-271.
62. Ziemssen, T; Kern, S. Psychoneuroimmunology-Cross-talk between the immune and nervous systems. J. Neurol., 2007, 254 Suppl 2, II8-II11.